Regulatory press release16.09.2024 klo 21.00Asarina Pharma AB (publ) shares to be delisted and the last day of trading is 1 October 2024
Regulatory press release13.09.2024 klo 12.00Asarina Pharma applies for the delisting of the company's shares
Regulatory press release21.08.2024 klo 12.30Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma
Regulatory press release22.07.2024 klo 09.00NOTICE OF EXTRAORDINARY GENERAL MEETING AND FIRST CONTROL MEETING IN ASARINA PHARMA AB (PUBL)
Regulatory press release18.07.2024 klo 18.45ASARINA PHARMA ANNOUNCES OUTCOME OF PARTNERING PROCESS, CONTROL BALANCE SHEET AND PROPOSAL TO LIQUIDATE
Regulatory press release27.06.2024 klo 12.33Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
Regulatory press release28.05.2024 klo 23.00Asarina Pharma AB announces new date for the release of Annual Report for 2023
Regulatory press release21.05.2024 klo 12.50Asarina Pharma AB announces new date for the release of Annual Report for 2023
Regulatory press release30.11.2023 klo 11.30Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB
Regulatory press release23.08.2023 klo 09.30Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)
Regulatory press release23.05.2023 klo 10.02Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders
Regulatory press release22.05.2023 klo 12.15Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
Regulatory press release05.05.2023 klo 14.33Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America
Regulatory press release18.04.2023 klo 11.39Asarina Pharma: NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)
Regulatory press release01.04.2023 klo 15.20Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome